Developer docs
API playgroundTry for free, no card

Search company profiles

Matricel

Full company profile

uuid000ukwz

Namestring
Matricel
Legal namestring
Matricel GmbH
Websiteurl
matricel.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Matricel GmbH develops, manufactures, and markets bioresorbable Class III medical devices based on proprietary collagen scaffold technologies for regenerative medicine applications. Founded in 2001 as a spin-off from the Helmholtz Institute of RWTH Aachen University and headquartered in Herzogenrath, Germany, the company operates as a subsidiary of Envista Holdings Corporation and employs 11–50 people. Its core technology platform combines proprietary directional solidification and freeze-drying to produce open-porous collagen matrices with oriented channel structures, EDC/NHS zero-length cell-compatible crosslinking that controls biodegradation without toxic residuals, and high-purity collagen and elastin extraction from veterinary-controlled animal sources.

The commercial product portfolio is anchored by Remaix (and its Nobel Biocare-branded variant creos xenoprotect), a bioresorbable dental collagen/elastin barrier membrane for guided bone and tissue regeneration (GBR/GTR), and ACI-Maix/Cartimaix bioresorbable membranes used in cartilage defect treatment, including as a key component of Vericel's MACI autologous chondrocyte implant under a long-term supply agreement. Research-stage products extend the platform into dermal regeneration (Novomaix, CE-marked 2013 for full-thickness burn and reconstructive surgery defects), peripheral nerve guidance (Neuromaix), and endochondral bone-cartilage ossification (E.CH.O). All products are manufactured in GMP-compliant cleanroom facilities in Germany, with clinical development supported by collaborations with RWTH Aachen, Fraunhofer ILT, Forschungszentrum Jülich, and EU consortiums.

The business model combines direct medical device sales with multi-channel distribution: Nobel Biocare globally distributes dental membranes under the creos xenoprotect brand across Europe, the US (post-FDA 2013), Canada (2015), and Mexico/Central America (Cofepris 2015); 2med GmbH distributes Cartimaix in Germany and Austria; and Matricel sells directly to hospitals, burn wound centers, dental clinics, and orthopedic surgery departments. A secondary revenue stream comes from contract manufacturing of collagen-containing products for pharmaceutical and medical device manufacturers, plus supply of pharmaceutical excipients. Pricing is quote-based B2B enterprise pricing, with no public price disclosure. Regulatory clearances across Europe (CE 2009), the US (FDA 2013), Canada, and Mexico underpin the global commercial reach.

Short descriptiontext

Matricel GmbH is a German medical device manufacturer producing bioresorbable Class III collagen implants and membranes (Remaix, ACI-Maix, Cartimaix, creos xenoprotect) for dental, orthopedic cartilage, dermal, and nerve regeneration, serving clinicians, hospitals, and OEM medical-device partners globally through distribution partnerships and contract manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHerzogenrath, Germany
HQ citystring
Herzogenrath
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
collagen medical implants, bioresorbable barrier membranes, regenerative medicine devices, dental tissue regeneration, cartilage repair membranes
Industry4 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SIC code3 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
  • Dental Equipment & Supplies3843
Product category
Regenerative Medicine Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeOne Time License
Description

Sale of bioresorbable Class III collagen implants for regenerative medicine applications including dental GBR/GTR (Remaix), orthopedic cartilage regeneration (Cartimaix), and skin regeneration (Novomaix). Products are approved in Europe, US, Canada and other territories.

matricel.com
2Contract Manufacturing
TypeProfessional Services
Description

Contract manufacturing services for pharmaceutical companies and medical device manufacturers, producing collagen-containing products to specification.

matricel.com
3Pharmaceutical Excipients
TypeOne Time License
Description

Development and supply of pharmaceutical excipients for applications in medicine and biotechnology.

matricel.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1B2B enterprise pricing through distribution partners and direct sales
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Sales through Nobel Biocare distribution network for dental products. Quote-based pricing for direct enterprise customers.

matricel.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Remaix
Description

Bioresorbable collagen barrier membrane for guided bone regeneration (GBR) and guided tissue regeneration (GTR) in dental applications.

matricel.com
+6 more records
Core offering1 text field

Matricel develops, manufactures, and markets bioresorbable Class III collagen implants for regenerative medicine applications, including dental barrier membranes (Remaix, creos xenoprotect), cartilage regeneration membranes (ACI-Maix, Cartimaix), dermal regeneration matrices (Novomaix), nerve guidance conduits (Neuromaix), and bone-cartilage scaffolds (E.CH.O). The company also provides contract manufacturing services for collagen-containing products to pharmaceutical and medical device firms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Slower biodegradation rate compared to other non-crosslinked collagen membranes in comparative studies
+2 more records
Product overview1 text field

Matricel develops, manufactures, and markets bioresorbable collagen implant products for regenerative medicine applications. The product portfolio centers on Class III medical devices including Remaix (dental barrier membrane for GBR/GTR), ACI-Maix and Cartimaix (cartilage regeneration membranes), and creos xenoprotect (dental membrane distributed via Nobel Biocare). Research-stage products include Novomaix (dermal regeneration), Neuromaix (nerve regeneration conduits), and E.CH.O (bone-cartilage scaffold). All products are developed and produced in Germany using proprietary collagen processing and open-porous scaffold technologies.

Product and service9 records
1Remaix
CategoryDental Barrier Membrane
Description

Bioresorbable dental barrier membrane for guided bone regeneration (GBR) and guided tissue regeneration (GTR), composed of highly purified porcine collagen and elastin fibers. Provides reliable barrier function while supporting natural tissue regeneration.

2Neuromaix
CategoryNerve Guidance Conduit
Description

Nerve regeneration collagen conduits with internal longitudinal microchannels for directional nerve fiber regeneration in reconstructive surgery for peripheral nerve defects.

3Novomaix
CategoryDermal Regeneration Matrix
Description

Dermal regeneration matrix intended to stimulate regeneration of dermal tissue as a basis for attachment of autologous split-skin mesh grafts or cultured keratinocyte sheets for treatment of full-thickness skin defects after burns or plastic reconstructive surgery.

4E.CH.O (Endochondral Cartilage Ossification)
CategoryBone-Cartilage Scaffold
Description

Mechano-hybrid scaffold for endochondral ossification of large bone and bone-cartilage defects.

5ACI-Maix
CategoryCartilage Regeneration Membrane
Description

Collagen membrane used in the manufacture of MACI (autologous cultured chondrocyte implant) for treatment of symptomatic full-thickness cartilage defects of the knee.

6Cartimaix
CategoryCartilage Regeneration Membrane
Description

Bioresorbable collagen membrane for coverage of joint cartilage defects following bone marrow-stimulating procedures, used for traumatic and degenerative lesions on surfaces of large joints.

7creos xenoprotect
CategoryDental Barrier Membrane
Description

Dental collagen barrier membrane for tissue regeneration procedures, distributed by Nobel Biocare. Features high tensile strength, excellent handling, and long stability against degradation without chemical crosslinking.

8Contract Manufacturing Services
CategoryContract Manufacturing
Description

Contract manufacturing services for pharmaceutical companies and medical device manufacturers, producing collagen-containing products to specification under GMP standards.

9Pharmaceutical Excipients
CategoryPharmaceutical Excipients
Description

Development and supply of pharmaceutical excipients based on collagen for applications in medicine and biotechnology.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2015-11-24
Description

Global distribution partnership for dental collagen barrier membranes under the creos xenoprotect brand. Distribution covers Europe, US (FDA 2013), Canada (2015), and Mexico/Central America (2015 COFEPRIS approval).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-10-26
Description

Long-term supply agreement for ACI-Maix collagen membrane used in MACI (Matrix-Induced Autologous Chondrocyte Implantation) for treating symptomatic full-thickness cartilage defects of the knee. Matricel previously supplied membranes when MACI was marketed by Genzyme outside the US.

32med GmbH
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2013-12-05
Description

Distribution cooperation for Cartimaix bioresorbable collagen membrane for orthopedic cartilage regeneration. 2med distributes in Germany and Austria, combining Cartimaix with their NanoFx system for nanofrakturierung procedures.

matricel.com
4Genzyme Corporation (Sanofi)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Close cooperation in the field of articular cartilage regeneration. Genzyme previously marketed MACI using Matricel's ACI-Maix collagen membrane outside the US.

matricel.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Joint development of new collagen-ceramic foam products for clinical use in bone regeneration. Development of composite sponge products combining ceramic bone substitutes with collagen.

6EuroSkinGraft Consortium
Strategic tierMajorTypeStrategic or Co-development Partner
Description

EU 7th Framework Programme project coordinated by PD Dr. Ernst Reichmann, University of Zurich. Multicenter clinical studies comparing innovative treatment concepts for full thickness dermal wounds in Switzerland, Netherlands, and Germany.

matricel.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Close cooperation on nerve regeneration project (Neuromaix) developing collagen nerve guidance conduits with internal guidance structures for reconstructing peripheral nerve defects.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Clinical research cooperation with Prof. Middelkoop on Novomaix dermal regeneration matrix for burn wound treatment.

9Pauwelsklinik Aachen
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical research partner for nerve regeneration and other tissue engineering projects.

matricel.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Funding and research support for preclinical studies on Novomaix dermal regeneration matrix.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medical device leader with wound management (including collagen-based wound dressings) and orthopedics franchises — a comparable large incumbent across multiple of Matricel's served indications.

TypeBroad incumbent
Description

Danish wound and skin care company with collagen-containing wound care products (e.g., Biatain, Purilon) competing in the same hospital/burn wound center channel where Matricel sells Novomaix directly.

TypeBroad incumbent
Description

Global orthopedic medical device giant with an extensive orthobiologics portfolio (bone graft substitutes, cartilage repair, sports medicine) — directly comparable on the orthopedic side of Matricel's business including Cartimaix and ACI-Maix.

TypeDirect peer
Description

US cell-therapy company marketing MACI (autologous chondrocyte implantation) which uses Matricel's ACI-Maix collagen membrane — both a key customer and adjacent competitor in cartilage regeneration.

TypeBroad incumbent
Description

Multi-billion-dollar US medical device company with broad regenerative medicine portfolios including Integra Dermal Regeneration Template and NeuraGen nerve conduits — directly comparable to Matricel's Novomaix (dermal) and Neuromaix (nerve) programs.

6botiss biomaterials
TypeDirect peer
Description

Germany-based dental regeneration specialist offering collagen membranes (e.g., collacone, Jason membrane) directly competing with Matricel's Remaix and creos xenoprotect in the same European dental customer base.

TypeBroad incumbent
Description

US publicly-traded regenerative medicine company focused on wound care and surgical recovery with placental/amniotic and other biologic skin substitutes — direct overlap with Matricel's burn/skin regeneration positioning.

TypeDirect peer
Description

US nerve repair specialist selling Avance nerve allograft and related products for peripheral nerve reconstruction — a direct competitor to Matricel's Neuromaix collagen nerve guidance conduit program.

TypeBroad incumbent
Description

Public regenerative medicine company with Apligraf and Dermagraft skin substitute products in wound care/burn indications, directly comparable to Matricel's Novomaix dermal regeneration matrix on therapeutic indication.

TypeDirect peer
Description

Swiss-headquartered leader in dental bone and tissue regeneration, including the widely used Bio-Gide collagen membrane — Matricel's most direct functional competitor in guided bone/tissue regeneration (GBR/GTR) membranes.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Matricel

Regenerative Medicine Medical Devicesmatricel.com

Matricel GmbH is a German medical device manufacturer producing bioresorbable Class III collagen implants and membranes (Remaix, ACI-Maix, Cartimaix, creos xenoprotect) for dental, orthopedic cartilage, dermal, and nerve regeneration, serving clinicians, hospitals, and OEM medical-device partners globally through distribution partnerships and contract manufacturing.

What Matricel does

Matricel GmbH develops, manufactures, and markets bioresorbable Class III medical devices based on proprietary collagen scaffold technologies for regenerative medicine applications. Founded in 2001 as a spin-off from the Helmholtz Institute of RWTH Aachen University and headquartered in Herzogenrath, Germany, the company operates as a subsidiary of Envista Holdings Corporation and employs 11–50 people. Its core technology platform combines proprietary directional solidification and freeze-drying to produce open-porous collagen matrices with oriented channel structures, EDC/NHS zero-length cell-compatible crosslinking that controls biodegradation without toxic residuals, and high-purity collagen and elastin extraction from veterinary-controlled animal sources.

The commercial product portfolio is anchored by Remaix (and its Nobel Biocare-branded variant creos xenoprotect), a bioresorbable dental collagen/elastin barrier membrane for guided bone and tissue regeneration (GBR/GTR), and ACI-Maix/Cartimaix bioresorbable membranes used in cartilage defect treatment, including as a key component of Vericel's MACI autologous chondrocyte implant under a long-term supply agreement. Research-stage products extend the platform into dermal regeneration (Novomaix, CE-marked 2013 for full-thickness burn and reconstructive surgery defects), peripheral nerve guidance (Neuromaix), and endochondral bone-cartilage ossification (E.CH.O). All products are manufactured in GMP-compliant cleanroom facilities in Germany, with clinical development supported by collaborations with RWTH Aachen, Fraunhofer ILT, Forschungszentrum Jülich, and EU consortiums.

The business model combines direct medical device sales with multi-channel distribution: Nobel Biocare globally distributes dental membranes under the creos xenoprotect brand across Europe, the US (post-FDA 2013), Canada (2015), and Mexico/Central America (Cofepris 2015); 2med GmbH distributes Cartimaix in Germany and Austria; and Matricel sells directly to hospitals, burn wound centers, dental clinics, and orthopedic surgery departments. A secondary revenue stream comes from contract manufacturing of collagen-containing products for pharmaceutical and medical device manufacturers, plus supply of pharmaceutical excipients. Pricing is quote-based B2B enterprise pricing, with no public price disclosure. Regulatory clearances across Europe (CE 2009), the US (FDA 2013), Canada, and Mexico underpin the global commercial reach.

Matricel firmographics

Firmographics
Name
Matricel
Legal name
Matricel GmbH
Website
https://matricel.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Matricel GmbH is a German medical device manufacturer producing bioresorbable Class III collagen implants and membranes (Remaix, ACI-Maix, Cartimaix, creos xenoprotect) for dental, orthopedic cartilage, dermal, and nerve regeneration, serving clinicians, hospitals, and OEM medical-device partners globally through distribution partnerships and contract manufacturing.
Ownership category
akta.pro rank

Matricel industry classification

Industry
Product category
Regenerative Medicine Medical Devices
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Collagen medical implants
  • Bioresorbable barrier membranes
  • Regenerative medicine devices
  • Dental tissue regeneration
  • Cartilage repair membranes

Where Matricel is headquartered

Location

Headquarters

HQ city
Herzogenrath
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Matricel business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of bioresorbable Class III collagen implants for regenerative medicine applications including dental GBR/GTR (Remaix), orthopedic cartilage regeneration (Cartimaix), and skin regeneration (Novomaix). Products are approved in Europe, US, Canada and other territories.
  2. Contract Manufacturing: Contract manufacturing services for pharmaceutical companies and medical device manufacturers, producing collagen-containing products to specification.
  3. Pharmaceutical Excipients: Development and supply of pharmaceutical excipients for applications in medicine and biotechnology.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B enterprise pricing through distribution partners and direct sales

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Matricel product offering

Product offering

Core offering

Matricel develops, manufactures, and markets bioresorbable Class III collagen implants for regenerative medicine applications, including dental barrier membranes (Remaix, creos xenoprotect), cartilage regeneration membranes (ACI-Maix, Cartimaix), dermal regeneration matrices (Novomaix), nerve guidance conduits (Neuromaix), and bone-cartilage scaffolds (E.CH.O). The company also provides contract manufacturing services for collagen-containing products to pharmaceutical and medical device firms.

Product overview

Matricel develops, manufactures, and markets bioresorbable collagen implant products for regenerative medicine applications. The product portfolio centers on Class III medical devices including Remaix (dental barrier membrane for GBR/GTR), ACI-Maix and Cartimaix (cartilage regeneration membranes), and creos xenoprotect (dental membrane distributed via Nobel Biocare). Research-stage products include Novomaix (dermal regeneration), Neuromaix (nerve regeneration conduits), and E.CH.O (bone-cartilage scaffold). All products are developed and produced in Germany using proprietary collagen processing and open-porous scaffold technologies.

Differentiator

Problem solved

Functional benefit

Brands

  • Remaix: Bioresorbable collagen barrier membrane for guided bone regeneration (GBR) and guided tissue regeneration (GTR) in dental applications.
  • Neuromaix
  • Novomaix
  • E.CH.O
  • creos xenoprotect
  • ACI-Maix
  • Cartimaix

Products and services

  • Remaix Bioresorbable dental barrier membrane for guided bone regeneration (GBR) and guided tissue regeneration (GTR), composed of highly purified porcine collagen and elastin fibers. Provides reliable barrier function while supporting natural tissue regeneration.
  • Neuromaix Nerve regeneration collagen conduits with internal longitudinal microchannels for directional nerve fiber regeneration in reconstructive surgery for peripheral nerve defects.
  • Novomaix Dermal regeneration matrix intended to stimulate regeneration of dermal tissue as a basis for attachment of autologous split-skin mesh grafts or cultured keratinocyte sheets for treatment of full-thickness skin defects after burns or plastic reconstructive surgery.
  • E.CH.O (Endochondral Cartilage Ossification) Mechano-hybrid scaffold for endochondral ossification of large bone and bone-cartilage defects.
  • ACI-Maix Collagen membrane used in the manufacture of MACI (autologous cultured chondrocyte implant) for treatment of symptomatic full-thickness cartilage defects of the knee.
  • Cartimaix Bioresorbable collagen membrane for coverage of joint cartilage defects following bone marrow-stimulating procedures, used for traumatic and degenerative lesions on surfaces of large joints.
  • creos xenoprotect Dental collagen barrier membrane for tissue regeneration procedures, distributed by Nobel Biocare. Features high tensile strength, excellent handling, and long stability against degradation without chemical crosslinking.
  • Contract Manufacturing Services Contract manufacturing services for pharmaceutical companies and medical device manufacturers, producing collagen-containing products to specification under GMP standards.
  • Pharmaceutical Excipients Development and supply of pharmaceutical excipients based on collagen for applications in medicine and biotechnology.

Quantifiable outcome

  • Slower biodegradation rate compared to other non-crosslinked collagen membranes in comparative studies
  • +2 more outcomes

Companies that use Matricel

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Matricel technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Matricel partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and minor.

  • Nobel BiocarecoreChannel Partner/ Reseller/ Distributor · 24 November 2015Global distribution partnership for dental collagen barrier membranes under the creos xenoprotect brand. Distribution covers Europe, US (FDA 2013), Canada (2015), and Mexico/Central America (2015 COFEPRIS approval).
  • Vericel CorporationcoreStrategic or Co-development Partner · 26 October 2015Long-term supply agreement for ACI-Maix collagen membrane used in MACI (Matrix-Induced Autologous Chondrocyte Implantation) for treating symptomatic full-thickness cartilage defects of the knee. Matricel previously supplied membranes when MACI was marketed by Genzyme outside the US.
  • 2med GmbHmajorChannel Partner/ Reseller/ Distributor · 5 December 2013Distribution cooperation for Cartimaix bioresorbable collagen membrane for orthopedic cartilage regeneration. 2med distributes in Germany and Austria, combining Cartimaix with their NanoFx system for nanofrakturierung procedures.
  • Genzyme Corporation (Sanofi)majorStrategic or Co-development PartnerClose cooperation in the field of articular cartilage regeneration. Genzyme previously marketed MACI using Matricel's ACI-Maix collagen membrane outside the US.
  • curasan AGmajorStrategic or Co-development PartnerJoint development of new collagen-ceramic foam products for clinical use in bone regeneration. Development of composite sponge products combining ceramic bone substitutes with collagen.
  • EuroSkinGraft ConsortiummajorStrategic or Co-development PartnerEU 7th Framework Programme project coordinated by PD Dr. Ernst Reichmann, University of Zurich. Multicenter clinical studies comparing innovative treatment concepts for full thickness dermal wounds in Switzerland, Netherlands, and Germany.
  • Clinic for Plastic and Reconstructive Surgery, RWTH AachenmajorStrategic or Co-development PartnerClose cooperation on nerve regeneration project (Neuromaix) developing collagen nerve guidance conduits with internal guidance structures for reconstructing peripheral nerve defects.
  • Burns Research Institute, Beverwijk, NLmajorStrategic or Co-development PartnerClinical research cooperation with Prof. Middelkoop on Novomaix dermal regeneration matrix for burn wound treatment.
  • Pauwelsklinik AachenminorStrategic or Co-development PartnerClinical research partner for nerve regeneration and other tissue engineering projects.
  • Nederlandse Brandwonden Stichting (Dutch Burns Foundation)minorStrategic or Co-development PartnerFunding and research support for preclinical studies on Novomaix dermal regeneration matrix.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Matricel competitors and assessment

Company assessment

Broad incumbents

  • Smith+Nephew: Global medical device leader with wound management (including collagen-based wound dressings) and orthopedics franchises — a comparable large incumbent across multiple of Matricel's served indications.
  • Coloplast: Danish wound and skin care company with collagen-containing wound care products (e.g., Biatain, Purilon) competing in the same hospital/burn wound center channel where Matricel sells Novomaix directly.
  • Stryker: Global orthopedic medical device giant with an extensive orthobiologics portfolio (bone graft substitutes, cartilage repair, sports medicine) — directly comparable on the orthopedic side of Matricel's business including Cartimaix and ACI-Maix.
  • Integra LifeSciences: Multi-billion-dollar US medical device company with broad regenerative medicine portfolios including Integra Dermal Regeneration Template and NeuraGen nerve conduits — directly comparable to Matricel's Novomaix (dermal) and Neuromaix (nerve) programs.
  • MiMedx: US publicly-traded regenerative medicine company focused on wound care and surgical recovery with placental/amniotic and other biologic skin substitutes — direct overlap with Matricel's burn/skin regeneration positioning.
  • Organogenesis: Public regenerative medicine company with Apligraf and Dermagraft skin substitute products in wound care/burn indications, directly comparable to Matricel's Novomaix dermal regeneration matrix on therapeutic indication.

Direct peers

  • Vericel Corporation: US cell-therapy company marketing MACI (autologous chondrocyte implantation) which uses Matricel's ACI-Maix collagen membrane — both a key customer and adjacent competitor in cartilage regeneration.
  • botiss biomaterials: Germany-based dental regeneration specialist offering collagen membranes (e.g., collacone, Jason membrane) directly competing with Matricel's Remaix and creos xenoprotect in the same European dental customer base.
  • Axogen: US nerve repair specialist selling Avance nerve allograft and related products for peripheral nerve reconstruction — a direct competitor to Matricel's Neuromaix collagen nerve guidance conduit program.
  • Geistlich Biomaterials: Swiss-headquartered leader in dental bone and tissue regeneration, including the widely used Bio-Gide collagen membrane — Matricel's most direct functional competitor in guided bone/tissue regeneration (GBR/GTR) membranes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Matricel social profiles

Digital presence

Matricel financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Matricel leadership team

Management profile

Number of profiles

Profiles4 records

Matricel funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Matricel M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Matricel

What does Matricel do?

Matricel develops, manufactures, and markets bioresorbable Class III collagen implants for regenerative medicine applications, including dental barrier membranes (Remaix, creos xenoprotect), cartilage regeneration membranes (ACI-Maix, Cartimaix), dermal regeneration matrices (Novomaix), nerve guidance conduits (Neuromaix), and bone-cartilage scaffolds (E.CH.O). The company also provides contract manufacturing services for collagen-containing products to pharmaceutical and medical device firms.

Is Matricel a public or private company?

Matricel is a private company. It is classified as corporate owned and is currently operating.

When was Matricel founded?

Matricel was founded in 2001. It employs 11 to 50 people.

Where is Matricel based?

Matricel is headquartered in Herzogenrath, Germany, in the Europe region.

How does Matricel make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are contract Manufacturing and pharmaceutical Excipients.

Who are Matricel's main competitors?

Broad incumbents on record are Smith+Nephew, Coloplast, Stryker, Integra LifeSciences, MiMedx and Organogenesis. Direct peers are Vericel Corporation, botiss biomaterials, Axogen and Geistlich Biomaterials.

Does Matricel have an API?

No public API is recorded for Matricel.

What industry is Matricel in?

Matricel's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales